Loss of ASRGL1 expression is an independent biomarker for disease-specific survival in endometrioid endometrial carcinoma
Loss of ASRGL1 expression is an independent biomarker for disease-specific survival in endometrioid endometrial carcinoma
复制标题
DOI：
10.1016/j.ygyno.2015.03.055
复制
发表时间：
2015-06-01
影响因子：
4.7
通讯作者：
Auranen, Annika
中科院分区：
文献类型：
--
作者：
Edqvist, Per-Henrik D.;Huvila, Jutta;Auranen, Annika
Objective.对于子宫内膜癌，预后分层方法不能令人满意地识别不良预后的患者。目前，组织学、肿瘤分级和分期用于定制手术治疗和确定是否需要辅助治疗。低风险患者不认为需要辅助治疗或分期淋巴结切除术。对于中度或高度风险的患者，一些指南建议根据其他负面预后因素调整辅助治疗。我们的目的是评估ASRGL 1蛋白在子宫内膜癌中的生物标志物潜力。使用人类蛋白质图谱（www.proteinatlas.org），L-天冬酰胺酶（ASRGL 1）蛋白被鉴定为子宫内膜癌生物标志物候选物。ASRGL 1表达用一种广泛验证的抗体在两个独立的子宫内膜癌组群（n = 229和n = 286）上进行免疫组织化学评价，所述两个组群排列为组织微阵列。染色结果与临床特征相关。ASRGL 1表达降低，定义为
Objective. For endometrial carcinoma, prognostic stratification methods do not satisfactorily identify patients with adverse outcome. Currently, histology, tumor grade and stage are used to tailoring surgical treatment and to determine the need for adjuvant treatment Low-risk patients are not considered to require adjuvant therapy or staging lymphadenectomy. For patients with intermediate or high risk, some guidelines recommend tailoring adjuvant treatment according to additional negative prognostic factors. Our objective was to evaluate the biomarker potential of the ASRGL1 protein in endometrial carcinoma.Methods. Using The Human Protein Atlas (www.proteinatlas.org), the L-asparaginase (ASRGL1) protein was identified as an endometrial carcinoma biomarker candidate. ASRGL1 expression was immunohistochemically evaluated with an extensively validated antibody on two independent endometrial carcinoma cohorts (n = 229 and n = 286) arranged as tissue microarrays. Staining results were correlated with clinical features.Results. Reduced expression of ASRGL1, defined as